Focused On-demand Library for Poly(A) RNA polymerase GLD2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6PIY7

UPID:

GLD2_HUMAN

Alternative names:

PAP-associated domain-containing protein 4; Terminal nucleotidyltransferase 2; Terminal uridylyltransferase 2

Alternative UPACC:

Q6PIY7; Q86WZ2; Q8N927

Background:

Poly(A) RNA polymerase GLD2, also known as PAP-associated domain-containing protein 4, Terminal nucleotidyltransferase 2, and Terminal uridylyltransferase 2, is a cytoplasmic enzyme. It specializes in adding AMP monomers to the 3'-end of specific RNAs, creating a poly(A) tail. This process is crucial for the stabilization and activity of certain cytoplasmic mRNAs and miRNAs, distinguishing it from canonical nuclear poly(A) RNA polymerases.

Therapeutic significance:

Understanding the role of Poly(A) RNA polymerase GLD2 could open doors to potential therapeutic strategies.